Observational Study for Lung Cancer Patients Treated With Nivolumab (EVIDENS)

Bristol-Myers Squibb (BMS)

Status: Completed

Conditions: Lung Cancer

Treatments: Other: Non-Interventional

Study type: Observational

Funder types: Industry

Identifiers

NCT03382496

CA209-417

Details and patient eligibility

About

This study will describe the characteristics of patients initiating nivolumab treatment for lung cancer and their outcomes over 3 years in France

Enrollment: 1,462 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male or female: 18 age at the time of nivolumab initiation
• Pathologically confirmed diagnosis of lung cancer
• Patient initiating nivolumab :therapeutic decision to initiate nivolumab must be taken by the physician prior to enrolling a patient in the study

Exclusion criteria

-Patient taking part in an interventional study for lung cancer treatment for which nivolumab is 1 of the investigational drugs

Other protocol defined inclusion or exclusion criteria could apply

Trial design

1,462 participants in 1 patient group

Lung Cancer patients in France

Description:

Lung Cancer patients treated by nivolumab in real life condition in France from October 2016 to October 2017

Treatment:

Other: Non-Interventional